会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • TRICYCLIC ANTIBIOTICS
    • 三环类抗生素
    • EP2721034A1
    • 2014-04-23
    • EP12728438.8
    • 2012-06-11
    • Basilea Pharmaceutica AG
    • GAUCHER, BérangèreDANEL, Franck HubertXIE, TongXU, Lin
    • C07D491/14C07D491/147
    • C07D498/04C07D491/052C07D491/14C07D491/147C07D495/04
    • Compounds of formula (I), wherein A1 represents -0-, -S- or -CH
      2 -; A2 represents -CH
      2 - or -0-; A3 represents C
      3 -C
      8 cycloalkylene; saturated or unsaturated 4 to 8-membered heterocyclodiyl with 1, 2 or 3 heteroatoms selected from nitrogen or oxygen, which group A3 is unsubstituted or substituted; A4 represents C
      1 -C
      4 alkylene, -C(=0)-; G represents aryl or heteroaryl, which is unsubstituted or substituted; X1 represents a nitrogen atom or CR1; R1 represents a hydrogen atom or a halogen atom; R2 represents a hydrogen atom; m is 0 or 1; n is 1; the -(CH
      2 )
      n - group is unsubstituted or substituted; p is 0 or 1; or pharmaceutically acceptable salts thereof are valuable for use as a medicament for the treatment of bacterial infections.
    • 式(I)化合物,其中A 1表示-O - , - S-或-CH 2 - A2代表-CH 2或-O-; A3代表C 3 -C 8亚环烷基; 具有1,2或3个选自氮或氧的杂原子的饱和或不饱和的4至8元杂环二基,该基团A3是未取代的或取代的; A4代表C 1 -C 4亚烷基,-C(= O) - ; G代表未经取代或经取代的芳基或杂芳基; X1代表氮原子或CR1; R1代表氢原子或卤素原子; R2代表氢原子; m是0或1; n是1; - (CH 2)n - 基团是未取代的或取代的; p是0或1; 或其药学上可接受的盐对于用作治疗细菌感染的药物有价值。
    • 5. 发明公开
    • TRICYCLIC ANTIBIOTICS
    • Tricyclische Antibiotika
    • EP2513115A1
    • 2012-10-24
    • EP10793255.0
    • 2010-12-17
    • Basilea Pharmaceutica AG
    • GAUCHER, BérangèreDANEL, Franck, HubertTANG, XiaoHuXIE, TongXU, Lin
    • C07D491/04C07D495/04A61K31/4741A61K31/4743A61P31/04
    • C07D513/04C07D491/04C07D491/052C07D491/147C07D495/04C07D498/04C07D498/14
    • Compound of formula (I): wherein A1 represents -O-, -S- or -N-R3; A2 represents -CH
      2 -, -O-, -N-R4, -C(=O)- or -CH(O-R4)-; A3 represents C
      3 -C
      8 cycloalkylene; saturated and unsaturated 4 to 8-membered heterocyclodiyl with 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulphur, which group A3 is unsubstituted or substituted; A4 represents C
      1 -C
      4 alkylene, C
      2 -C
      4 alkenylene, >C=O or a group selected from - C
      2 H
      4 NH-, -C
      2 H
      4 O-, and -C
      2 H
      4 S- being linked to the adjacent NR5-group via the carbon atom; and G represents aryl or heteroaryl, which is unsubstituted or substituted and R1 and R2 independently of one another, represent hydrogen or a substituent selected from hydroxy, halogen, mercapto, cyano, nitro, C
      1 -C
      6 alkyl, C
      1 -C
      6 alkoxy, C
      1 -C
      6 alkylthio, C
      1 -C
      6 alkylcarbonyloxy, C
      1 -C
      6 alkylsulfonyloxy, C
      1 -C
      6 heteroalkylcarbonyloxy, C5-C
      6 heterocyclylcarbonyloxy, C
      1 -C
      6 heteroalkoxy, wherein heteroalkyl, heteroalkoxy groups or heterocyclyl comprise 1, 2 or 3 heteroatoms selected from nitrogen, oxygen and sulphur, in which substituents the alkyl moieties are unsubstituted or further substituted; R3, R4 and R5 independently of one another, represent hydrogen or C
      1 -C
      6 alkyl; X1 and X2 independently of one another, represent a nitrogen atom or CR2, with the proviso that at least one of Xl and X2 represents a nitrogen atom; m is 1; and the (CH2)m moiety is optionally substituted by C
      1 -C
      4 alkyl; halogen, carboxy, hydroxy, C
      1 -C
      4 alkoxy, C
      1 -C
      4 -alkylcarbonyloxy, amino, mono- or di-(C
      1 -C
      4 alkyl)amino or acylamino n is 0, 1 or 2 or pharmaceutically acceptable salt thereof are valuable for use as a medicament for the treatment of bacterial infections.